End-stage renal disease (ESRD) also known as end-stage renal failure is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. In this condition, kidneys are only functioning at 10–15% of their normal capacity. A patient with end-stage renal failure must receive dialysis or kidney transplantation in order to survive for more than a few weeks.
Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of the end-stage renal disease (ESRD). Approximately 30–40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market
The End-Stage Renal Disease (ESRD) market report also covers emerging drugs, current treatment practices, End-Stage Renal Disease (ESRD) market share of the individual therapies, current and forecasted End-Stage Renal Disease (ESRD) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current End-Stage Renal Disease (ESRD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
End-Stage Renal Disease (ESRD) Market Key Facts
-
ESRD is more common in men than women; however, statistics vary little across different regions. Based on the US Renal Data System (USRDS) annual data report, the prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%). However, in the most recent US Renal Data System, 57.8% of the patients with a new-onset ESRD were men
-
According to the National Center for Chronic Disease Prevention and Health Promotion, about 15% of adults in the US are estimated to have chronic kidney disease. Chronic kidney disease can often be treated before it progresses to end-stage renal failure or leads to other health problems
-
The study conducted by Abbasi et al., titled “End-stage renal disease” estimates that the prevalence of ESRD in the US in 2007 was 1,698 cases per million population. In 2007, Japan also observed a relatively high prevalence, i.e., 2,060 cases per million population of ESRD, which included only people receiving maintenance dialysis
- The Center for Disease Control and Prevention (CDC) estimated that as of December 2016, 0.7 million patients were being treated for end-stage renal disease (ESRD) in the United States, giving a point prevalence of 2,206 per million population; the prevalence of dialysis treatment was 1,553 per million, whereas the prevalence of functioning kidney transplant was 653 per million.
Key Benefits of End-Stage Renal Disease (ESRD) Market Report
-
The report provides an in-depth analysis of End-Stage Renal Disease (ESRD) Market Size and Share, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The End-Stage Renal Disease (ESRD) market report will help in developing business strategies by understanding the End-Stage Renal Disease (ESRD) Market trends & developments, key players, and future market competition that will shape and drive the End-Stage Renal Disease (ESRD) market in the upcoming years.
-
The End-Stage Renal Disease (ESRD) market report covers End-Stage Renal Disease (ESRD) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the End-Stage Renal Disease (ESRD) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
End-Stage Renal Disease (ESRD) Market
The End-Stage Renal Disease (ESRD) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted End-Stage Renal Disease (ESRD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the End-Stage Renal Disease (ESRD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
End-Stage Renal Disease (ESRD) Epidemiology
The End-Stage Renal Disease (ESRD) epidemiology section covers insights about the historical and current End-Stage Renal Disease (ESRD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
End-Stage Renal Disease (ESRD) Drugs Uptake and Key Market Players
The End-Stage Renal Disease (ESRD) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the End-Stage Renal Disease (ESRD) market or expected to get launched in the market during the study period. The analysis covers End-Stage Renal Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
End-Stage Renal Disease (ESRD) market size is expected to increase during the forecast period owing to the growing prevalence of the disease in the 7MM.
End-Stage Renal Disease (ESRD) companies:
Aronora
Merck
Rockwell Medical Technologies
Dynavax Technologies Corporation
And many others.
End-Stage Renal Disease (ESRD) therapies covered in the report include:
Intravenous Triferic
AB002
MK-2060
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. End-Stage Renal Disease (ESRD) Competitive Intelligence Analysis
4. End-Stage Renal Disease (ESRD) Market Overview at a Glance
5. End-Stage Renal Disease (ESRD) Disease Background and Overview
6. End-Stage Renal Disease (ESRD) Patient Journey
7. End-Stage Renal Disease (ESRD) Epidemiology and Patient Population
8. End-Stage Renal Disease (ESRD) Treatment Algorithm, Current Treatment, and Medical Practices
9. End-Stage Renal Disease (ESRD) Unmet Needs
10. Key Endpoints of End-Stage Renal Disease (ESRD) Treatment
11. End-Stage Renal Disease (ESRD) Marketed Products
12. End-Stage Renal Disease (ESRD) Emerging Therapies
13. End-Stage Renal Disease (ESRD) Seven Major Market Analysis
14. Attribute Analysis
15. End-Stage Renal Disease (ESRD) Market Outlook (7 major markets)
16. End-Stage Renal Disease (ESRD) Access and Reimbursement Overview
17. KOL Views on the End-Stage Renal Disease (ESRD) Market.
18. End-Stage Renal Disease (ESRD) Market Drivers
19. End-Stage Renal Disease (ESRD) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports
End-Stage Renal Disease (ESRD) Epidemiology Forecast
DelveInsight’s End-Stage Renal Disease (ESRD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of End-Stage Renal Disease (ESRD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/